

Table S1 Univariable and multivariable analysis of the impact of treatment groups on CSP patients with and without adverse events

Treatment Group	Cases, n (%)	Univariable analysis		Multivariable analysis*	
		OR (95% CI)	P value	OR (95% CI)	P value
No treatment	226 (82.9%)	1.000 (reference)	–	1.000 (reference)	–
Other treatment only	31 (11.4%)	3.583 (1.419–9.031)	0.007	0.779 (0.135–4.509)	0.781
Any UAE/MTX use	16 (5.9%)	0.687 (0.861–5.474)	0.723	0.346 (0.025–4.707)	0.425

*, covariates: gestational age, gestational mass size, presence of a GS, RMT, localization types, RMT, exact extent of protrusion, vascularity supplying. CSP, cesarean scar pregnancy; OR, odds ratio; CI, confidence interval; UAE, uterine artery embolization; MTX, methotrexate; GS, gestation sac; RMT, minimum residual myometrial thickness.

Table S2 Comparison of preoperative interventions effects between primary and sensitivity analyses

Preoperative interventions	Primary multivariable model*		Sensitivity analysis*	
	OR (95% CI)	P value	OR (95% CI)	P value
No	1.00 (reference)	–	1.00 (reference)	–
Yes	0.634 (0.124–3.248)	0.585	0.465 (0.070–3.086)	0.428

*, covariates: gestational age, gestational mass size, presence of a GS, RMT, localization types, RMT, exact extent of protrusion, vascularity supplying. CI, confidence interval; CSP, cesarean scar pregnancy; GS, gestation sac; OR, odds ratio; RMT, minimum residual myometrial thickness.

Table S3 Interaction analysis between treatment modalities

Interaction Terms	OR (95% CI)	P value
Main Effects		
Other treatment only (vs. none)	0.741 (0.125–4.393)	0.743
Any UAE/MTX use (vs. none)	0.272 (0.193–3.838)	0.324
Interaction Effects		
Other treatment only × any UAE/MTX use	1.000	>0.05

OR, odds ratio; CI, confidence interval; UAE, uterine artery embolization; MTX, methotrexate; GS, gestation sac.